Maze Therapeutics, Inc. (MAZE) Stock

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc. is led by CEO Jason V. Coloma, publicly traded since 2025.

Maze Therapeutics, Inc. (MAZE) stock trades at $31.01 with a market capitalization of $1.72B. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.65, reflecting a net loss over the last twelve months, price-to-book of 3.44, price-to-sales of 73.14. Over the past 52 weeks the stock has ranged between $21.95 and $53.65, and currently trades 42.2% below its 52-week high.

On profitability, Maze Therapeutics, Inc. generates a return on equity (ROE) of -34.94% (negative, reflecting a net loss), return on capital employed of -28.63%, an operating margin of -6.70%, a net profit margin of -667.95%.

Maze Therapeutics, Inc. by the numbers, 2022–2025

Between 2022 and 2025 Maze Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-131.0M.

The most recent net margin is -667.95%. On a trailing twelve-month basis to Jun '26, revenue is $20.0M and net profit $-134.0M.

Borrowings fell from $32.0M to $23.0M, cash from operations was $-112.0M in the latest year, positive in 1 of the last 4.

Return on equity has averaged -281.1% over five years, and was -36.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Maze Therapeutics, Inc. (MAZE) — frequently asked questions